At the news
? NEUTRALIMPACT 2/10 PRESS-RELEASE filed Apr 17, 2026 at 17:15 ET
Iovance Biotherapeutics granted inducement stock options covering 135,470 shares to twelve new non-executive employees, priced at $3.80 per share with three-year vesting. This is a routine hiring incentive and does not reflect a material strategic or financial change.
- Iovance granted stock options for 135,470 shares to twelve new non-executive employees.
- Options were granted under the 2021 Inducement Plan, compliant with Nasdaq Rule 5635(c)(4).
- Exercise price is $3.80, equal to the closing price on the grant date (April 16, 2026).
- Vesting: one-third on first anniversary, remainder over eight quarterly installments thereafter.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access